Hitting a complex target: an update on interleukin-6 trans-signalling
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Interleukin-6 (IL-6) is a key target in inflammation and cancer. Selective inhibition of IL-6 trans-signalling could provide the same or even higher therapeutic efficacy with a better side effect profile than complete IL-6 inhibition. Animal studies with IL-6 inhibitors show that the classic IL-6 signalling pathway via the membrane-bound IL-6 receptor (IL-6R) has important physiological functions, whereas blocking the trans-signalling pathway via the soluble IL-6R (sIL-6R) is sufficient to prevent or treat IL-6-driven diseases. Due to the success of the anti-IL-6R antibody tocilizumab and difficulties of constructing selective trans-signalling inhibitors, most drug candidates in clinical development target IL-6 or IL-6R and, thus, both IL-6 pathways. By contrast, the fusion protein sgp130Fc selectively targets IL-6/sIL-6R trans-signalling by utilising the soluble gp130 receptor as the natural inhibitor of trans-signalling. AREAS COVERED: The authors summarise recent developments in the field with a focus on animal studies highlighting the mechanistic differences between classic and trans-signalling and their therapeutic implications. EXPERT OPINION: Characterising disease mechanisms in terms of the employed IL-6 pathways will help to select the right therapeutic IL-6 inhibitor in the future. The trans-signalling inhibitor sgp130Fc is about to enter the clinic and holds promise for a clinically different profile in comparison with complete IL-6 inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212 · cited 10×
“In contrast to other cytokines, the sIL-6R is not an inhibitor of IL-6 but a stabiliser [11] and, in the form of the IL-6/sIL-6R complex, a potent agonist of gp130 signalling on practically all cells in the body [3,4].”
BackgroundResultInfluentialSelf-citationGrivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155
Self-citationImpaired immune and acute-phase responses in interleukin-6-deficient mice
Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., Zinkernagel, R., Bluethmann, H., & Köhler, G. (1994) · Nature · doi:10.1038/368339a0 · Cited by 1,768 · cited 1×
“Interestingly, IL-6 was also shown to protect the intestinal epithelium from apoptosis during infection by the lesion-inducing pathogen Citrobacter rodentium [61], which is in line with the previously reported protective role of IL-6 in diverse intestinal infections [62-64].”
ResultAtreya, R., Mudter, J., Finotto, S., Müllberg, J., Jostock, T., Wirtz, S., Schütz, M., Bartsch, B., Holtmann, M., Becker, C., et al. (2000) · Nature Medicine · doi:10.1038/75068 · Cited by 1,293
Self-citationInterleukin-6-deficient mice develop mature-onset obesity
Wallenius, V., Wallenius, K., Ahrén, B., Rudling, M., Carlsten, H., Dickson, S. L., Ohlsson, C., & Jansson, J.-O. (2002) · Nature Medicine · doi:10.1038/nm0102-75 · Cited by 1,213 · cited 1×
“This is in line with the finding that IL-6 mice developed late-onset obesity [29,30], hepatic inflammation and systemic insulin resistance [30].”
ResultBollrath, J., Phesse, T. J., von Burstin, V. A., Putoczki, T., Bennecke, M., Bateman, T., Nebelsiek, T., Lundgren-May, T., Canli, Ö., Schwitalla, S., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.002 · Cited by 946 · cited 2×
“This may mask or confound significant therapeutic efficacy of trans-signalling inhibition in disease models where IL-6 classic signalling has a beneficial effect [56,57,60,61].”
BackgroundLesina, M., Kurkowski, M. U., Ludes, K., Rose-John, S., Treiber, M., Klöppel, G., Yoshimura, A., Reindl, W., Sipos, B., Akira, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.009 · Cited by 862
Self-citationHumanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease
Nishimoto, N., Kanakura, Y., Aozasa, K., Johkoh, T., Nakamura, M., Nakano, S., Nakano, N., Ikeda, Y., Sasaki, T., Nishioka, K., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4602 · Cited by 754
Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance
Matthews, V. B., Allen, T. L., Risis, S., Chan, M. H. S., Henstridge, D. C., Watson, N., Zaffino, L. A., Babb, J. R., Boon, J., Meikle, P. J., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1865-y · Cited by 334 · cited 1×
“This is in line with the finding that IL-6 mice developed late-onset obesity [29,30], hepatic inflammation and systemic insulin resistance [30].”
ResultInterleukin-6 regulates pancreatic α-cell mass expansion
Ellingsgaard, H., Ehses, J. A., Hammar, E. B., Van Lommel, L., Quintens, R., Martens, G., Kerr-Conte, J., Pattou, F., Berney, T., Pipeleers, D., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801059105 · Cited by 269
IL-6 Trans-Signaling Modulates TLR4-Dependent Inflammatory Responses via STAT3
Greenhill, C. J., Rose-John, S., Lissilaa, R., Ferlin, W., Ernst, M., Hertzog, P. J., Mansell, A., & Jenkins, B. J. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002971 · Cited by 264 · cited 2×
“A recent study by Greenhill and colleagues demonstrated promising efficacy of sgp130Fc in a model of lipopolysaccharide-mediated endotoxic shock, where anti-IL-6R and IL-6mice showed a similar phenotype [55] (Table 2).”
BackgroundSelf-citationNowell, M. A., Williams, A. S., Carty, S. A., Scheller, J., Hayes, A. J., Jones, G. W., Richards, P. J., Slinn, S., Ernst, M., Jenkins, B. J., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.613 · Cited by 215 · cited 3×
“Despite the lack of systematic comparisons between classic and transsignalling inhibition in arthritis models, data with natural sgp130 variants [44,45] and sgp130Fc [46] indicate that transsignalling may be the critical component in animal models of antigen-induced arthritis [44,45] and collagen-induced arthritis [46…”
BackgroundSelf-citationGarbers, C., Jänner, N., Chalaris, A., Moss, M. L., Floss, D. M., Meyer, D., Koch-Nolte, F., Rose-John, S., & Scheller, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.229393 · Cited by 201 · cited 1×
“In humans, IL-6R is shed by the membrane-bound protease ‘a disintegrin and metalloprotease17’ (ADAM17) [7,8], but the use of ADAM sheddases appears to be species specific [9].”
BackgroundSelf-citationJones, G. W., McLoughlin, R. M., Hammond, V. J., Parker, C. R., Williams, J. D., Malhotra, R., Scheller, J., Williams, A. S., Rose-John, S., Topley, N., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901528 · Cited by 189 · cited 2×
“Therefore, future studies featuring a direct comparison of anti-IL-6(R) and sgp130(Fc) could revisit and expand at least some of the strong evidence for therapeutic efficacy of trans-signalling inhibition in models of arthritis [44-46], spontaneous ileitis [47], acute peritonitis [45,48], inflammation-associated colon…”
BackgroundSelf-citationBarkhausen, T., Tschernig, T., Rosenstiel, P., van Griensven, M., Vonberg, R.-P., Dorsch, M., Mueller-Heine, A., Chalaris, A., Scheller, J., Rose-John, S., et al. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e318211ff56 · Cited by 169 · cited 6×
“This partial decrease probably represents the sum of positive (trans-signalling inhibition) and negative effects (blockade of epithelial regeneration) [60].”
BackgroundResultInfluentialSelf-citationNechemia-Arbely, Y., Shriki, A., Denz, U., Drucker, C., Scheller, J., Raub, J., Pappo, O., Rose-John, S., Galun, E., & Axelrod, J. H. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.017 · Cited by 42
Self-citation
Cited by
Rose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040
“These experiments allowed to decide whether the gp130 driven disease model was based on IL-6 classic signaling or IL-6 trans-signaling [54, 55].”
BackgroundMethodSelf-citationThe molecular details of cytokine signaling via the JAK/STAT pathway
Morris, R., Kershaw, N. J., & Babon, J. J. (2018) · Protein Science · doi:10.1002/pro.3519 · Cited by 943
Interleukin-6 and its receptors: a highly regulated and dynamic system
Wolf, J., Rose-John, S., & Garbers, C. (2014) · Cytokine · doi:10.1016/j.cyto.2014.05.024 · Cited by 618
“As a possible drug for treatment of inflammatory diseases, an optimized version of this inhibitor (FE999301) is currently tested in clinical phase I studies by Ferring Pharmaceuticals [4,20].”
BackgroundSelf-citationInterleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update
Su, H., Lei, C.-T., & Zhang, C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00405 · Cited by 524
The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition
Garbers, C., Aparicio-Siegmund, S., & Rose-John, S. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.02.008 · Cited by 429
Self-citation
Metadata
- Authors
- Waetzig, G. H., & Rose-John, S.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2012-02
- Volume
- 16
- Issue
- 2
- Pages
- 225-236
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2062926560
- Cited by
- 83
- References
- 16
- FWCI
- 6.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.